[HTML][HTML] Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII
RT Barrow, P Lollar - Journal of Thrombosis and Haemostasis, 2006 - Elsevier
Background: Inhibitory antibodies to factor (F) VIII (FVIII inhibitors) present a major clinical
challenge as a complication of hemophilia A and as acquired autoantibodies in non‐
hemophiliacs. Porcine FVIII is a potentially useful therapeutic agent because of its low
crossreactivity with many inhibitors. Recombinant porcine FVIII (rpFVIII) is undergoing
clinical trials in inhibitor patients. Objectives: The goals of this study were to neutralize
human FVIII inhibitors in vitro with rpFVIII and to characterize the relationship between …
challenge as a complication of hemophilia A and as acquired autoantibodies in non‐
hemophiliacs. Porcine FVIII is a potentially useful therapeutic agent because of its low
crossreactivity with many inhibitors. Recombinant porcine FVIII (rpFVIII) is undergoing
clinical trials in inhibitor patients. Objectives: The goals of this study were to neutralize
human FVIII inhibitors in vitro with rpFVIII and to characterize the relationship between …